Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
291
resultados
Última actualización
15/07/2026 [08:14:00]
Resultados 250 a 275 de 291
Resumen de: WO2017207739A1
The invention provides antibodies that specifically bind human Į-synuclein with a high affinity and reduces Į-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating Į-synuclein antibodies, and methods of using Į-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
Resumen de: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Resumen de: JP2026084774A
0001 【課題】構造異常タンパク質の蓄積を制御する物質を得ることができる翻訳調節剤のスクリーニング方法を提供する。 【解決手段】小胞体ストレス状態において翻訳と共役したタンパク質分解機構で分解される基質の翻訳調節剤のスクリーニング方法は、Ｓｅｃ６１βとＡＲＩＨ１との結合を促進又は抑制する被験物質を選択する結合評価ステップを含む。 【選択図】図２１
Resumen de: KR20260074177A
0001a 본 발명은 뇌신경계 질환 치료용 후보 약물의 스크리닝 방법에 관한 것으로, 실제 뇌 조직으로부터 GPCR을 포함한 단백질을 용해한 후, 활성형(GTPγS 결합형) 및 비활성형(GDP 결합형) G 단백질 알파 서브유닛 o(Gαo)과 상호작용하는 단백질을 분석함으로써 생리학적으로 보다 근접한 환경에서 후보 물질의 작용을 평가할 수 있으며, 뇌신경계 질환 치료에 유효한 후보 약물을 효율적으로 선별할 수 있다.
Resumen de: US20260140117A1
0000 Compositions, methods, and kits are provided for diagnosing and treating vestibular schwannoma. In particular, biomarkers associated with tumor growth and hearing loss have been identified that may be useful for diagnosing vestibular schwannoma and aid in determining the timing of tumor resection. These biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, or monitoring treatment of vestibular schwannoma.
Resumen de: US20260139036A1
0000 The present disclosure provides antigen binding regions and chimeric antibodies, as well as methods of making and using the same.
Resumen de: US20260140122A1
0000 Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and/or accumulation, for example amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and/or reagents.
Resumen de: AU2026203284A1
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided. pr p r
Resumen de: US20260137755A1
The disclosure relates to compositions and methods for treating a disease or condition associated with a TDP-pathology or a decline in TDP-43 functionality in neuronal cells in a subject, and for identifying candidate agents to restore expression of a normal full-length or protein coding STMN2 RNA.
Resumen de: US20260140106A1
The present invention related to a compound for use in prevention or treatment of a neurodegenerative disease associated with the formation of stress granules. The compound is selected from lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention further relates to a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and (b) determining the characteristic associated with the one or more condensates. A modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.
Resumen de: AU2026203151A1
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system. pr p r
Resumen de: AU2024376004A1
Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or in combination therapies.
Resumen de: US20260140060A1
0000 Methods, compositions, systems, matrices, and kits for determining a presence, type and/or amount of a viral biomarker in a sample by contacting the sample with one or more agents that selectively reacts with the biomarker and with a colorimetric indicator that exhibits a colorimetric change as a result of a reaction between the agent and a viral biomarker, are provided.
Resumen de: WO2026103842A1
A light-initiated chemiluminescence assay kit for phosphorylated Tau protein p-tau 217, a use method thereof and the use thereof. The kit comprises an R1 reagent, an R2 reagent and an R3 reagent. The R1 reagent comprises luminescent microspheres and first antibodies each of which coats a luminescent microsphere, has a first tag molecule and can specifically bind to p-tau 217. The R2 reagent comprises second antibodies carrying second tag molecules. The R3 reagent comprises first pairing molecules that can specifically bind to the first tag molecules. The first antibodies and the second antibodies can specifically bind to different epitopes of p-tau 217, and one first pairing molecule can bind to at least two first tag molecules.
Resumen de: AU2024363039A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: AU2024360083A1
Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.
Resumen de: AU2024355578A1
The present invention relates to a NLRP3 variant comprising at least a partial deletion of the PYD. The present invention further relates to a method of screening for a compound that inhibits the NLRP3 inflammasome. The present invention further provides a method comprising the step of administering a compound identified by such a screening method to a subject with a NLRP3-associated inflammatory disorder.
Resumen de: WO2026107335A1
Described herein are small interfering RNA (siRNA) molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of EF-hand domain-containing protein 1. Also, described herein are the use of said siRNA molecules in the treatment of metabolic liver disease, metabolic dysfunction-associated steatotic liver disease, or steatohepatitis, and reduces Ca2+-induced mitochondrial fission.
Resumen de: WO2026102542A1
The present disclosure relates to methods and compositions for ATPase inhibitors that regulate expression of EHMT1/2 and downstream genes SNRPN, and SNURF, increase histone acetylation and/or restoration of chromatin accessibility at target loci, and/or increase expression of KANSL1 and/or CREBBP. Methods useful for treating a disease associated with EHMT1/EHMT2 or modulated by EHMT1/EHMT2 inhibition and downstream gene expression (e.g. Prader-Willi Syndrome), or decreased histone acetylation and/or chromatin accessibility at target loci, and/or decreased expression of KANSL1 and/or CREBBP are disclosed.
Resumen de: WO2026103875A1
A light-initiated chemiluminescence detection method, a reagent, and a use. The detection method comprises: bringing a sample to be tested into contact with a reaction system comprising a first antibody and a second antibody, so as to obtain an immune reaction product, and measuring the optical signal intensity of the immune reaction product, the first antibody and/or the second antibody directionally coupling a non-specific binding region thereof to a target substance by means of an isopeptide bond. Alternatively, an R3 reagent is added on the basis of a conventional detection method, and at least two label molecules are bound by means of a pairing molecule contained in the R3 reagent, the label molecules being carried by the first antibody in luminescent microspheres, such that the at least two luminescent microspheres are aggregated into a multimeric luminescent microsphere. The detection method can improve the detection performance of light-initiated chemiluminescence, and meet detection requirements of a low-abundance sample such as p-tau217 in a blood sample.
Resumen de: WO2026106780A1
Implementations of a microphysiological system may include at least one first inlet for receiving a fluid medium; a fat module including adipocytes, the fat module configured to receive the fluid medium; a liver module including hepatocytes; a channel between the fat module and the liver module, the channel configured to promote communication of the fluid medium from the fat module to the liver module; and the channel configured for exchange of one or more of nutrients, signaling molecules, and drugs between the fat module and the liver module.
Resumen de: WO2026102485A1
The invention relates to pharmaceutical compositions and methods of treating or preventing immunological or inflammatory conditions, such as sepsis or septic shock. Also provided are methods of predicting the likelihood of a subject experiencing an immunological or inflammatory condition, such as sepsis or septic shock.
Resumen de: WO2026106937A1
Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.
Resumen de: US20260137692A1
0000 The present disclosure provides methods of diagnosing, characterizing, or treating diseases (e.g., Alzheimer's Disease) associated with phosphorylated tau proteins, including p-tau217 and p-tau243, in subjects in need thereof.
Nº publicación: US20260141984A1 21/05/2026
Solicitante:
FORESITE LABS LLC [US]
Foresite Labs, LLC
Resumen de: US20260141984A1
A system for reducing memory processing resources comprises one or more processors configured to generate a plurality of principal components (PCs) corresponding to characteristic data for entities in a dataset to reduce a size of the dataset; generate a score for each entity in the dataset based at least on (i) the PCs, and (ii) weights for a condition of interest; determine a set of alternates that correspond to the condition of interest; determine, using a machine learning model, interactions between the set of alternates for one or more target components corresponding to the object and the scores, wherein the interactions are indicative of a response for the condition of interest; and perform one or more actions.
BOPI
Sede Electrónica
